Drug Profile
COM 701
Alternative Names: anti-PVRIG antibody; CGEN-15029; COM-701; COM701/PVRIGLatest Information Update: 09 Nov 2023
Price :
$50
*
At a glance
- Originator Compugen
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD112 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 07 Nov 2023 Compugen completes enrolment in the I proof-of-concept study for Solid tumors in USA (IV)
- 28 Oct 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Monotherapy, Second-line therapy or greater) in USA (IV)
- 03 Oct 2023 Compugen has patent protection for "Triple Combination Antibodies Therapies" in Japan